Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy

Irene Casanova-Salas, José Rubio-Briones, Ana Calatrava, Caterina Mancarella, Esther Masiá, Juan Casanova, Antonio Fernández-Serra, Luis Rubio, Miguel Ramírez-Backhaus, Ana Armiñán, José Domínguez-Escrig, Francisco Martínez, Zaida García-Casado, Katia Scotlandi, María J. Vicent, José Antonio López-Guerrero

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Purpose miRNAs are noncoding RNAs that negatively regulate target mRNA gene expression. Aberrant miRNA expression is associated with prostate cancer pathogenesis. We identified miRNAs as potential biomarkers for prostate cancer diagnosis and prognosis. Materials and Methods Total RNA was obtained from 10 normal prostate and 50 prostate cancer samples, and analyzed using the GeneChip® miRNA 2.0 Array. At a median followup of 92 months (range 2 to 189) an independent cohort of 273 paraffin embedded prostate cancer samples was used for validation by quantitative reverse transcriptase-polymerase chain reaction. Another 92 urine samples from patients undergoing prostate biopsy were evaluated for these miRNAs. Results miR-182 and 187, the miRNAs most differentially expressed between normal and tumor tissue, were selected for further validation. miR-187 inversely correlated with cT (p = 0.125) and pT (p = 0.0002) stages, Gleason score (p = 0.003) and TMPRSS2-ERG status (p = 0.003). The log rank test showed associations of miR-182 with biochemical (p = 0.026) and clinical (p = 0.043) progression-free survival, as also noted on multivariate analysis. A significant independent improvement in the definition of risk of progression was achieved by combining miR-182 expression with Gleason score (p

Original languageEnglish
Pages (from-to)252-259
Number of pages8
JournalJournal of Urology
Volume192
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Prostatectomy
MicroRNAs
Early Diagnosis
Prostatic Neoplasms
Biomarkers
Neoplasm Grading
Prostate
Untranslated RNA
Reverse Transcriptase Polymerase Chain Reaction
Paraffin
Disease-Free Survival
Multivariate Analysis
Urine
RNA
Biopsy
Gene Expression
Messenger RNA
Neoplasms

Keywords

  • biological markers
  • diagnosis
  • microRNAs
  • prognosis
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. / Casanova-Salas, Irene; Rubio-Briones, José; Calatrava, Ana; Mancarella, Caterina; Masiá, Esther; Casanova, Juan; Fernández-Serra, Antonio; Rubio, Luis; Ramírez-Backhaus, Miguel; Armiñán, Ana; Domínguez-Escrig, José; Martínez, Francisco; García-Casado, Zaida; Scotlandi, Katia; Vicent, María J.; López-Guerrero, José Antonio.

In: Journal of Urology, Vol. 192, No. 1, 2014, p. 252-259.

Research output: Contribution to journalArticle

Casanova-Salas, I, Rubio-Briones, J, Calatrava, A, Mancarella, C, Masiá, E, Casanova, J, Fernández-Serra, A, Rubio, L, Ramírez-Backhaus, M, Armiñán, A, Domínguez-Escrig, J, Martínez, F, García-Casado, Z, Scotlandi, K, Vicent, MJ & López-Guerrero, JA 2014, 'Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy', Journal of Urology, vol. 192, no. 1, pp. 252-259. https://doi.org/10.1016/j.juro.2014.01.107
Casanova-Salas, Irene ; Rubio-Briones, José ; Calatrava, Ana ; Mancarella, Caterina ; Masiá, Esther ; Casanova, Juan ; Fernández-Serra, Antonio ; Rubio, Luis ; Ramírez-Backhaus, Miguel ; Armiñán, Ana ; Domínguez-Escrig, José ; Martínez, Francisco ; García-Casado, Zaida ; Scotlandi, Katia ; Vicent, María J. ; López-Guerrero, José Antonio. / Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. In: Journal of Urology. 2014 ; Vol. 192, No. 1. pp. 252-259.
@article{370710813d844eefa5ba7c96de613d2a,
title = "Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy",
abstract = "Purpose miRNAs are noncoding RNAs that negatively regulate target mRNA gene expression. Aberrant miRNA expression is associated with prostate cancer pathogenesis. We identified miRNAs as potential biomarkers for prostate cancer diagnosis and prognosis. Materials and Methods Total RNA was obtained from 10 normal prostate and 50 prostate cancer samples, and analyzed using the GeneChip{\circledR} miRNA 2.0 Array. At a median followup of 92 months (range 2 to 189) an independent cohort of 273 paraffin embedded prostate cancer samples was used for validation by quantitative reverse transcriptase-polymerase chain reaction. Another 92 urine samples from patients undergoing prostate biopsy were evaluated for these miRNAs. Results miR-182 and 187, the miRNAs most differentially expressed between normal and tumor tissue, were selected for further validation. miR-187 inversely correlated with cT (p = 0.125) and pT (p = 0.0002) stages, Gleason score (p = 0.003) and TMPRSS2-ERG status (p = 0.003). The log rank test showed associations of miR-182 with biochemical (p = 0.026) and clinical (p = 0.043) progression-free survival, as also noted on multivariate analysis. A significant independent improvement in the definition of risk of progression was achieved by combining miR-182 expression with Gleason score (p",
keywords = "biological markers, diagnosis, microRNAs, prognosis, prostatic neoplasms",
author = "Irene Casanova-Salas and Jos{\'e} Rubio-Briones and Ana Calatrava and Caterina Mancarella and Esther Masi{\'a} and Juan Casanova and Antonio Fern{\'a}ndez-Serra and Luis Rubio and Miguel Ram{\'i}rez-Backhaus and Ana Armi{\~n}{\'a}n and Jos{\'e} Dom{\'i}nguez-Escrig and Francisco Mart{\'i}nez and Zaida Garc{\'i}a-Casado and Katia Scotlandi and Vicent, {Mar{\'i}a J.} and L{\'o}pez-Guerrero, {Jos{\'e} Antonio}",
year = "2014",
doi = "10.1016/j.juro.2014.01.107",
language = "English",
volume = "192",
pages = "252--259",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy

AU - Casanova-Salas, Irene

AU - Rubio-Briones, José

AU - Calatrava, Ana

AU - Mancarella, Caterina

AU - Masiá, Esther

AU - Casanova, Juan

AU - Fernández-Serra, Antonio

AU - Rubio, Luis

AU - Ramírez-Backhaus, Miguel

AU - Armiñán, Ana

AU - Domínguez-Escrig, José

AU - Martínez, Francisco

AU - García-Casado, Zaida

AU - Scotlandi, Katia

AU - Vicent, María J.

AU - López-Guerrero, José Antonio

PY - 2014

Y1 - 2014

N2 - Purpose miRNAs are noncoding RNAs that negatively regulate target mRNA gene expression. Aberrant miRNA expression is associated with prostate cancer pathogenesis. We identified miRNAs as potential biomarkers for prostate cancer diagnosis and prognosis. Materials and Methods Total RNA was obtained from 10 normal prostate and 50 prostate cancer samples, and analyzed using the GeneChip® miRNA 2.0 Array. At a median followup of 92 months (range 2 to 189) an independent cohort of 273 paraffin embedded prostate cancer samples was used for validation by quantitative reverse transcriptase-polymerase chain reaction. Another 92 urine samples from patients undergoing prostate biopsy were evaluated for these miRNAs. Results miR-182 and 187, the miRNAs most differentially expressed between normal and tumor tissue, were selected for further validation. miR-187 inversely correlated with cT (p = 0.125) and pT (p = 0.0002) stages, Gleason score (p = 0.003) and TMPRSS2-ERG status (p = 0.003). The log rank test showed associations of miR-182 with biochemical (p = 0.026) and clinical (p = 0.043) progression-free survival, as also noted on multivariate analysis. A significant independent improvement in the definition of risk of progression was achieved by combining miR-182 expression with Gleason score (p

AB - Purpose miRNAs are noncoding RNAs that negatively regulate target mRNA gene expression. Aberrant miRNA expression is associated with prostate cancer pathogenesis. We identified miRNAs as potential biomarkers for prostate cancer diagnosis and prognosis. Materials and Methods Total RNA was obtained from 10 normal prostate and 50 prostate cancer samples, and analyzed using the GeneChip® miRNA 2.0 Array. At a median followup of 92 months (range 2 to 189) an independent cohort of 273 paraffin embedded prostate cancer samples was used for validation by quantitative reverse transcriptase-polymerase chain reaction. Another 92 urine samples from patients undergoing prostate biopsy were evaluated for these miRNAs. Results miR-182 and 187, the miRNAs most differentially expressed between normal and tumor tissue, were selected for further validation. miR-187 inversely correlated with cT (p = 0.125) and pT (p = 0.0002) stages, Gleason score (p = 0.003) and TMPRSS2-ERG status (p = 0.003). The log rank test showed associations of miR-182 with biochemical (p = 0.026) and clinical (p = 0.043) progression-free survival, as also noted on multivariate analysis. A significant independent improvement in the definition of risk of progression was achieved by combining miR-182 expression with Gleason score (p

KW - biological markers

KW - diagnosis

KW - microRNAs

KW - prognosis

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84902537523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902537523&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2014.01.107

DO - 10.1016/j.juro.2014.01.107

M3 - Article

C2 - 24518785

AN - SCOPUS:84902537523

VL - 192

SP - 252

EP - 259

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -